Clinical Trials Browser

Phase 2 × Metastatic Gastric Adenocarcinoma × apatinib × Clear all

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Metastatic Gastric Adenocarcinoma

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Metastatic Gastric Adenocarcinoma